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Background/aim: It was aimed to evaluate the results of Rose Bengal (RB), ELISA total tests (IgM and IgG), and the Brucella Coombs
gel test (BCGT), which are used as screening tests, with the combined results of a tube agglutination test (standard Wright test: SWT)
and a tube agglutination test with antihuman globulin (AHG TAT).
Materials and methods: Samples from 97 patients prediagnosed with brucellosis (age ≥18 years) were screened with RB, ELISA, and
BCGT. SWT < 160 samples and RB-negative but ELISA- or BCGT-positive samples were tested by AHG TAT. SWT ≥ 160 or AHG TAT
≥ 160 was taken as reference.
Results: Thirty-two of 56 RB-positive samples and one RB-negative but ELISA- and BCGT-positive sample were found to be ≥160
with SWT or AHG TAT. Sensitivity, specificity, accuracy, and agreement (kappa) values according to SWT ≥ 160 or AHG TAT ≥ 160
positivity were as follows, respectively: RB 96.9%, 62.5%, 74.2%, and 0.509; ELISA total 100%, 60.9%, 74.2%, and 0.515; BCGT test 97%,
70.3%, 79.4%, and 0.594.
Conclusion: Sensitivities of the screening tests are similar, but positivities should be confirmed by more specific tests. Positive samples
from screening tests should be tested with AHG if the SWT value is <160.
Key words: Serological tests, brucellosis, ELISA, Brucella Coombs gel test

1. Introduction
Brucellosis is a systemic zoonotic infection disease in
humans affecting various organs and systems, which
causes a wide variety of clinical presentations. The acute
phase may progress to a chronic disease with relapse or
development of persistent localized infection. Subacute
brucellosis is a typical form with undulant fever (1–3).
Mortality is rare and usually results from infection of the
brain or heart, as endocarditis with severe destruction
of valve structures is the most frequent cause of death
in brucellosis (4,5). Brucellosis incidence reported from
endemic regions worldwide is <0.01 and may be as high
as >200 per 100,000 people. It is estimated that the real
incidence is more than 25 times the reported values (2).
While the gold standard for the diagnosis of brucellosis
is culture, it requires a long incubation period, there is a
risk of laboratory infection, and isolation of the etiologic
agent varies according to disease phase, antibiotic use,
Brucella species, and culture medium (3,2,6,7). Antibody
* Correspondence: drmanyas@me.com
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tests are widely used because of these reasons. Positive
results with the Rose Bengal (RB) slide agglutination test,
which is used as a screening test, should be supported by
other methods such as titrimetric tests (2,6,7–10). There is
a problem in defining a diagnostic titer in a single sample
and it may change according to the prevalence of the
population, but a titer of ≥160 is mostly accepted (6,7–11).
Blocking antibodies found in chronic cases are IgG
(IgG1 and IgG2) and IgA antibodies, which can specifically
bind to the antigen without visible agglutination. Presence
of blocking antibodies in the serum can be shown by
Coombs test (antihuman globulin: AHG) or BrucellaCapt
test (6,7,9,10,12).
Alternative methods, such as the enzyme-linked
immunosorbent assay (ELISA) and AHG gel test, with
which more samples in shorter time periods can be
tested, are presented against standardization problems
of agglutination tests with the possibility of different
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evaluations by different people in different laboratories, but
evaluation of these tests is necessary before substitution
(6–8,13–16).
In this study, it was aimed to evaluate the results of RB,
ELISA total tests (IgM and IgG), and the Brucella Coombs
(AHG) gel test (BCGT), which were used as screening
tests, with the combined results of a tube agglutination
titration test (standard Wright test: SWT) and the AHG
tube agglutination test (AHG TAT).
2. Material and methods
2.1. Samples
Samples from 97 patients prediagnosed with brucellosis
and aged 18 years or older, which were sent to the Medical
Microbiology Laboratory of the Ege University Medical
Faculty between 07.01.2014 and 29.01.2015, were included
in the study. The ethical committee approved the study on
07.01.2014 (number 13-12.1/8).

2.2. Serological tests
The RB test (Türk Halk Sağlığı Kurumu, Turkey), ELISA
IgM and IgG tests (Vircell, Spain), and BCGT (1/40
dilution) (Odak Brucella Coombs gel test, Toprak Medikal,
Turkey) were used as screening tests. The SWT (Türk Halk
Sağlığı Kurumu) and AHG test (Millipore, UK) were used
as titrimetric tests.
2.3. Study algorithm
All the samples were screened with RB, ELISA IgM, ELISA
IgG, and BCGT. RB-positive samples were tested by SWT
(TAT). Samples positive with RB but SWT-negative or
with titers lower than 160 and samples negative with RB
but positive with ELISA IgM and/or IgG or BCGT were
tested by AHG TAT to investigate presence of blocking
antibodies. SWT or AHG TAT positivity with titers of ≥160
were accepted for the confirmation of laboratory diagnosis.
The study algorithm of the samples is summarized in
Figure 1.

SAMPLES OF
PATIENTS
PREDIAGNOSED
WITH BRUCELLOSIS
97
SCREENING TESTS
RB
ELISA IgM and IgG
BCGT (1/40)
RB po s itive

RB negati ve

SWT

ELISA IgM /IgG and/or BCGT
positive

1/160

< 1/ 16 0
AHG TAT

POSITIVE

AHG TAT

1/160

1/160
POSITIVE

POSITIVE
Figure 1. Study algorithm of the samples from 97 patients prediagnosed with brucellosis.
RB: Rose Bengal test, SWT: standard Wright test, BCGT: Brucella Coombs gel test, AHG
TAT: tube agglutination test with antihuman globulin.
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2.4. Statistical methods
Sensitivity, specificity, and accuracy of RB, ELISA total
tests (IgM and/or IgG positivity), and the BCGT were
determined by taking SWT or AHG TAT positivity with
titers of ≥160 as a reference. Agreement of test results
with SWT or AHG TAT ≥160 positivity was analyzed by
calculating kappa evaluation coefficients and kappa values
between 0.21 and 0.40 were interpreted as weak, 0.41–0.60
as intermediate, 0.61–0.80 as good, and >0.80 as excellent
correlation (17).
3. Results
3.1. Results of screening tests
Among the 97 samples, at least one screening test was
positive in 52 cases and in 46 of them all three screening
tests (RB, ELISA total, BCGT) were positive. Distribution
of samples according to the results of screening tests is
shown in Figure 2.
3.2. SWT results
Of the 56 RB-positive samples, 22 were found to be ≥160
positive and 34 were <160 or negative.
3.3. AHG TAT results
Thirty-four RB-positive samples that were SWT negative
or <160, two RB-negative samples that were ELISA totaland BCGT-positive, and four samples that were only ELISA
total-positive were tested by AHG TAT to investigate the
presence of blocking antibodies. Among these 40 samples,
five of the RB-positives increased to 160, four increased to
640, and one increased to 320, and one RB-negative sample
that was ELISA total- and BCGT-positive increased to a
titer of 160.
Results of the 97 samples with the study algorithm are
summarized in Figure 3.
3.4. Sensitivity, specificity, accuracy, and agreement
(kappa value)
These values for RB, ELISA total (IgM + IgG), BCGT, and
BCGT of ≥160 according to SWT ≥160 or AHG TAT ≥160
positivity are shown in the Table.

4. Discussion
Diagnosis of probable brucellosis is made by confirmation
of clinical and laboratory findings with specific
microbiological tests. Isolation of Brucella species form
blood, bone marrow, and tissue samples is accepted as the
gold standard. However, the isolation rate of the etiological
agent varies according to stage of the disease, antibiotic
use, Brucella species, culture medium, and technique used
and it may be low in relapses (2,3,8). Identification of the
agent by polymerase chain reaction has not been accepted
as a standard diagnostic tool (2,3,7). For these reasons,
antibody tests are widely used in brucellosis diagnosis. The
specificity of the RB test, which has been used as a screening
test for many years, varies according to the prevalences
of the populations and confirmation of positive results
with titrimetric tests is required (1,2,6,7,11,18–21). Even
though a SWT titer of ≥160 in the presence of associated
epidemiological (exposure history) and clinical findings
is generally accepted for the diagnosis of brucellosis, the
diagnostic titer for the confirmation of the disease has
not been clearly identified (2,8,19,22). The diagnostic titer
needs to be evaluated according to the prevalence of the
disease in the area where the patient lives (rural or urban)
and the features of the studied population (for example,
occupational risk factors) (2,6,7,9,10,12).
In this study, a single serum sample was evaluated
and a titer of ≥160 by SWT or AHG TAT was added to
the algorithm for samples negative or with low titers to
investigate the blocking antibodies. Thirty-two of 56
RB-positive samples were confirmed with ≥160 SWT
or ≥160 AHG positivity. One sample that was RBnegative but positive by BCGT (1/40) and ELISA total
tests was found to be 1/160 positive by AHG TAT. RB
sensitivity and specificity were determined as 96.9% and
62.5%, respectively by taking SWT ≥160 or AHG TAT
≥160 positive samples as a reference. RB sensitivity and
specificity rates were reported between 75% and 100%
in studies done with active brucellosis cases (11,18–21).
It is observed that RB sensitivity and specificity rates

SCREENING TESTS (97 samples)

All
screening
tests N
(35)

All
screening
tests P
(46)

Only one screening test P
Only RB P (1)
Only ELISA total P (4)

Two of the screening tests P
RB P; ELISA total P; BCGT N (6)
RB P; ELISA total N; BCGT P (3)
RB N; ELISA total P; BCGT P (2)

Figure 2. Distribution of samples according to the results of screening tests. P: Positive, N: negative.
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SAMPLES OF PATIENTS
PREDIAGNOSED WITH
BRUCELLOSIS
97
SCREENING TESTS
RB
ELISA IgM and IgG
BCGT (1/40)

SWT

RB po sitive

RB negat ive

(56)

(41)

1/160
(22)

POSITIVE
(22)

SWT < 1/ 16 0
(34)

ELISA total

only ELISA total
positive
(4)

and BCGT positive
(2 )

AHG 1/160
(10 )
POSITIVE
(10)

AHG 1/160
(1 )

AHG 1/160
(0 )

POSITIVE
(1)

Figure 3. Algorithm of serological tests used for brucellosis serodiagnosis and the number of
samples found to be positive (number). RB: Rose Bengal test, SWT: standard Wright test, AHG:
tube agglutination test with antihuman globulin, BCGT: Brucella Coombs gel test.
Table. Sensitivity, specificity, accuracy, and kappa values according to SWT ≥160 or AHG TAT ≥160
positivity.

RB

Sensitivity

Specificity

Accuracy

Kappa*

P**

96.9%

62.5%

74.2%

0.509

0.000

ELISA IgM

75.5%

87.5%

83.5%

0.633

0.000

ELISA IgG

87.8%

68.8%

75.3%

0.507

0.000

ELISA total

100%

60.9%

74.2%

0.515

0.000

BCGT (1/40)

97%

70.3%

79.4%

0.594

0.000

BCGT ≥160

78.8%

93.8%

88.7%

0.742

0.000

*Kappa value of 0.21–0.40 is defined as weak, 0.41–0.60 as medium, 0.61–0.80 as good, and >0.80 as near
to excellent agreement.
**P-value for kappa analysis.

increase to 100% in studies that take culture positivity as a
reference, while they decrease even to 33%–50% in special
patient groups such as chronic, complicated, and focal
infections (7,20,21). It is also suggested to increase the test
time to 8 min for blocking antibodies in chronic patients

(8,20). However, we performed the test in 4 min and have
not tried 8 min.
The presence of blocking antibodies in the serum can
be demonstrated by Coombs agglutination test (AHG
TAT) or BrucellaCapt test. Binding of blocking antibodies
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can be induced by adding AHG IgG (Coombs reagent)
mechanically (centrifugation at high speed) (2,7,8–10,12).
AHG is included in the BCGT that we used in our study
and binding of blocking antibodies with AHG is induced
with high speed centrifugation to make it possible to get
higher titers than in the SWT. In our study, sensitivity of
BCGT screening with 1/40 dilution of sera as suggested by
the producer was found as 97%, while the specificity was
70.3%. Sensitivity rates of BCGT reported in other studies
from Turkey (94%–100%) are similar to ours, while the
specificity rate we found is lower than the reported 82%–
100% rates (13-16). İrvem et al. (13) reported excellent
agreement with AHG TAT and an immunocapture
agglutination test. In our study, medium agreement (kappa
= 0.594) with SWT/AHG TAT ≥160 positivity and 79.4%
accuracy were found. When we evaluated the BCGT
with a titer of ≥160, sensitivity decreased to 78.8% while
the specificity increased to 93.8%, accuracy increased to
88.7%, and agreement became good (kappa = 0.742). It is
necessary to evaluate the titrimetric results of the BCGT,
which was developed in Turkey and has started to be used
recently, with more studies and longer follow-up periods
to demonstrate its clinical value.
Brucella ELISA tests, which were presented as an
alternative for laboratory diagnosis to overcome the
problems of agglutination tests, have varying sensitivity
and specificity rates depending on different kits; in some
tests rates as low as 50% were reported (22–25). IgM and
IgG sensitivity rates in active brucellosis cases are reported
as 80% separately, while when IgM and IgG results are
evaluated together, the sensitivity of the test increases to
90%–100% (22–25). It is suggested to perform rheumatoid
factor (RF) absorption routinely to prevent false positive

results due to RF in the serum (23). RF absorption is used
in the test we used in our study. In our study, IgM and
IgG sensitivities were found as 75.5% and 87.8%, while
specificities were found as 87.5% and 68.8%, respectively.
When IgM and IgG were evaluated in total to increase the
sensitivity, sensitivity was found as 100% but the specificity
decreased to 60.9%. Reported sensitivity rates with the
kit we used are similar, but our specificity rate is lower.
Binnicker et al. (26) found 82.7% of IgM-positive and only
54.2% of IgG-positive samples as negative with TAT, but
they did not use AHG. One of the important problems
of cross-reactions due to OPS structure also occur with
ELISA tests that use S-LPS antigen. This problem is seen
less with ELISA tests that use the whole cell (6,7,25). The B.
abortus S-99 LPS antigen is used in the kit we used.
In this presented study, the BCGT with ≥160 has the
highest accuracy and agreement values, followed by ELISA
IgM values. These results seem to be the reflection of their
high specificities. However, when their low sensitivities are
considered, it is not found to be appropriate to use them
as single tests alone. Both of the tests missed seven cases.
Limitations of our study can be summarized as the lack of
culture results and no follow-up of the patients. Titrimetric
values of the BCGT need to be evaluated in broader casebased studies.
In conclusion, a sensitive screening test should be used
and then confirmed with a more specific test. Samples
positive by screening test but SWT-negative or <160
should be tested with AHG.
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Doğanay M, Alp Meşe E. Bruselloz. In: Topçu AW, Söyletir G,
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